Background: Sevoflurane anesthetic has recently been administered by anesthesiologists during voiding cystourethrograms in a centre where radiologists are not permitted to deliver pediatric sedation. Objective: To determine whether sevoflurane is a satisfactory anesthetic agent for voiding cystourethrography in children.
Conclusion: Aucun ev enement ind esirable ou des effets sur la qualit e diagnostique du cysto-ur etrogramme mictionnel p ediatrique n'a et e observ e avec l'administration de s evoflurane. La majorit e des parents et tuteurs sond es estiment que l'anesth esie a rendu l'exp erience de la cysto-ur etrographie mictionnelle plus facile pour leur enfant. Ó 2012 Canadian Association of Radiologists. All rights reserved.
Key Words: Pediatric cystography anesthesia Voiding cystourethrography (VCUG) is a common fluoroscopic radiologic examination, which is used for detection of urinary tract abnormalities. It is frequently performed in children, with more than 530 examinations performed per year in our institution. It is an invasive procedure, which involves the insertion of a catheter into the urinary bladder and retrograde instillation of contrast medium. The examination may be psychologically traumatic for parents and patients alike [1, 2] . Sedation of selected pediatric patients is an accepted practice, and its use has been documented in the peer-reviewed literature [3e7] .
Pediatric sedation during VCUG, although used in current practice, has not been extensively researched. In a randomized double-blinded study, Stokland et al [4] demonstrated that the use of midazolam made the VCUG less distressing for both parents and patients. Keidan et al [8] compared the efficacy of oral midazolam and nitrous oxide, and found that they were comparable in reducing anxiety and distress but that nitrous oxide provided a more-rapid onset of sedation and a shorter recovery time. In the study by Schmit and Sfez [9] , rectal midazolam reduced pain and stress during VCUG in children of both sexes under age 5 years, but nitrous oxide only did so in girls. The use of intranasal fentanyl recently has been described to decrease pain on catheterization during VCUG but demonstrated no decrease in pain compared with placebo [10] . In many pediatric institutions, such as ours, radiologists are not permitted to deliver conscious sedation, based on local medical safety regulations. The task of providing sedation for children undergoing VCUG is given to the pediatric anesthesiologists, who prefer to use inhalational anesthetic agents such as sevoflurane. The use of this agent has been studied in pediatric magnetic resonance imaging [11, 12] , but, to date, no evaluation of the use of sevoflurane for the pediatric VCUG examination has been reported.
Sevoflurane is an ether inhalation anesthetic agent, which can be rapidly and conveniently administered without discomfort. Its low solubility facilitates precise control over the depth of anesthesia and a rapid and smooth induction of, and emergence from, general anesthesia [13] . The characteristics of rapid induction and emergence are ideal properties of an anesthetic agent for the purpose of a VCUG, with deeper anesthesia only required for a short time during bladder catheterization and rapid emergence that enables the patient to have regained consciousness sufficiently to cooperate with voiding on the fluoroscopy table. Sevoflurane has been extensively studied for induction and maintenance of anesthesia in children younger than 18 years old (usually American Society of Anesthesiologists class I and II) undergoing ambulatory (day-case or outpatient) surgery and, to a lesser extent, in nonambulatory surgery that lasts fewer than 5 hours [13] . Reported adverse effects include cough, laryngospasm, breath holding, agitation and/or excitement, nausea, vomiting, and malignant hyperthermia [13, 14] .
The objective of this study was to determine whether inhalational sevoflurane is a satisfactory anesthetic agent for obtaining a diagnostic voiding cystourethrogram in pediatric patients with respect to patient safety and acceptability, and the effect on the diagnostic quality of the examination.
Patients and Methods
A retrospective cohort study was performed on children undergoing anesthetized and unsedated VCUG at Stollery Children's Hospital between April 2004 and November 2008. The images and patient records of all patients undergoing VCUG under general anesthetic with sevoflurane as the sole anesthetic agent were reviewed for adverse effects from anesthetic, diagnostic quality of the VCUG, time from anesthetic to recovery, and time from recovery to discharge. A subset of 53 children who received sevoflurane for firsttime VCUG, with no history of vesicoureteral reflux (VUR), were identified. Records of a corresponding age-and sex-matched control group of 53 randomly selected children undergoing VCUG without sedation from the same time period as the subset of 53 children who received sevoflurane were reviewed with respect to diagnostic quality of the VCUG. The control group also had no history of VUR or VCUG. If more than one child matched in age and sex to a sevoflurane subject, then the child with the examination closest to the time of the sevoflurane subject was selected.
Children were referred for VCUG with anesthesia by their referring physician, mostly urologists, nephrologists, and pediatricians. Sevoflurane was administered by inhalation just before bladder catheterization, and administration terminated at the initiation of bladder filling. The VCUG images and reports were reviewed for diagnostic quality, particularly for the occurrence of on-table voiding, residual urine volume present within the bladder after micturition, presence and grade of VUR. VUR was graded by the international classification of VUR, where I represents reflux into a nondilated ureter; II represents reflux into the renal pelvis without dilatation; III represents mild dilatation of the ureter, renal pelvis, and calyces; IV represents moderate dilatation of the renal pelvis and calyces, with moderate ureteral tortuosity; and V represents gross dilatation of the collecting system, ureteral tortuosity, and loss of papillary impressions [15] . Where there was no reflux, VUR was graded as 0. If there was bilateral VUR, then the higher grade was recorded. The final recorded bladder image was taken as the postvoid image unless otherwise stated in the formal report. Residual volume was graded by dividing the pelvis into thirds ( Figure 1 ) with grade 1 (no or small residual volume), grade 2 (moderate residual volume, above the acetabulum), and grade 3 (large residual volume, above the mid sacroiliac joint). Residual bladder volume was only graded for patients who voided on the table. Age, postvoid residual bladder volumes, and VUR grade were compared between the sedated and unsedated groups by using the Student unpaired t test. The incidence of on-table voiding and VUR was compared between groups by using the Fisher exact test.
Parents remained with their child from admission to anesthetic induction, with most parents leaving during the time the child was unconscious, at the discretion of the anesthesiologist. Those parents who left after induction returned when the child began to regain consciousness. A follow-up questionnaire was sent to the child's parents after the procedure to assess their opinion of their child's experience with VCUG under sedation, with the same questionnaire administered by telephone to nonresponders within 1 month of the procedure (Table 1) . Confidence intervals for responses were calculated by using the modified Wald equation. The study was approved by the University of Alberta Health Research Ethics Board.
Results
From April 2004 to November 2008, all pediatric patients who underwent a VCUG with sevoflurane as the only anesthetic induction agent during bladder catheterization were included in the study. Ninety-six patients met inclusion criteria. Five patients were excluded for the following reasons, VCUG and Dimercaptosuccinic acid (DMSA) scans performed at the same visit (n ¼ 3), VCUG and eye examination at the same visit (n ¼ 1), and recovery room sheet not available from the medical record (n ¼ 1). Therefore, data were calculated on 91 examinations on 88 patients. Three patients had a second VCUG under sevoflurane anesthesia, with an intervening period of more than 1 year between studies.
The median patient age was 47 months (range, 10-195 months). There was a female predominance of patients (74%). Indications for VCUG included query VUR (n ¼ 54), follow-up VUR (n ¼ 33), duplex collecting system (n ¼ 1), bladder dysfunction (n ¼ 1), urethral stricture (n ¼ 1), multicystic dysplastic kidney (n ¼ 1), recurrent cystitis (n ¼ 1), and renal transplant (n ¼ 1).
Agitation was reported in examinations of 3 children (3%) by the recovery room staff. Other reported adverse effects included sore throat (n ¼ 1) and coughing (n ¼ 1). None of the known adverse effects of sevoflurane, such as laryngospasm, nausea, vomiting, and malignant hyperthermia, were reported by anesthesiologists or recovery room staff. No child visited the emergency department after the procedure for anesthetic or other complications. There were no reports of cardiac or respiratory events during or after anesthetic.
There were no radiologist reports of nondiagnostic VCUG examinations in children anesthetized with sevoflurane. Voiding occurred in 87 examinations (96%) in sedated children ( Table 2) . VUR was identified in all 4 children who did not void on the table. VUR was demonstrated in 48 children: 54% of girls and 46% of boys. The grade of reflux ranged from no reflux to grade IV, with a mean (SD) grade of 1.26 AE 1.51, median 0. Residual bladder volumes were graded as 1 (38%), 2 (32%), and 3 (28%) for patients who voided on the table, with a mean of 1.87, with 2 examinations having no postvoid image obtained.
The age-and sex-matched control unsedated group (Table 2 ) median age was 47 months, and 17% were boys, exactly the same as the sevoflurane group, with no previous VUR or VCUG (P > .9). Voiding occurred in 94% of examinations in both groups (P > .9), and reflux was Figure 1 . Residual bladder volume grading system. For grade I (minimal) volumes, the bladder was below the level of the acetabula, denoted by the lower line. Grade II (moderate) volumes were assigned when the bladder dome was above the acetabula but below the mid sacroiliac joint level (denoted by the upper line). Grade III (large) volumes were assigned when the bladder dome reached above the midpoint of the sacroiliac joints, denoted by the upper line. A right duplex collecting system with vesicoureteral reflux into both systems is present in this patient.
identified in none of the 3 control patients who did not void on the table. VUR was observed in 42% of studies, not significantly different than 36% in the corresponding sedated group (P ¼ .69). The mean grade of VUR was 1.08 for the control group and 0.81 for the sevoflurane group, with a range of 0-4, not a significant difference (P ¼ .28 A total of 42 patients' families participated in a questionnaire, but not all questions were answered by all respondents (Table 1) . A large proportion of children, 50%, had prior VCUG (95% confidence interval [CI], 35%-65%) or prior medical procedure, 75% (95% CI, 60%-86%). A minority of caregivers (35%) were present during the VCUG, with most of these (81%) reporting that they were comfortable with their child's coping during the procedure (95% CI, 51%-96%). The majority of parents (85%) thought that VCUG under sevoflurane was easier than before (unsedated) (95% CI, 63%-96%), and the same proportion of parents thought that sedation made the VCUG easier for the child (95% CI, 69%-94%). Most caregivers (76%) thought the child's experience of a VCUG under sevoflurane would make their child less anxious about future medical procedures (95% CI, 61%-87%).
Discussion
Sevoflurane was evaluated for patient safety and acceptability, and for the effect on the diagnostic quality of the VCUG. With regard to safety, there were no cardiorespiratory complications from sevoflurane anesthesia for VCUG, with no incidents reported in 91 events. This rate is comparable with the 0.4% rate reported by Sanborn et al [16] in a much larger series that evaluated sevoflurane adverse effects. Minor adverse effects, such as agitation, sore throat, and coughing were observed in a minority of patients after the anesthetic. Agitation or emergence delirium, which has been described with use of sevoflurane for imaging tests [11, 17] , was seen in 3% of patients in our study, which is lower than the 9% rate reported by Bryan [11] for sevoflurane during magnetic resonance imaging. A meta-analysis of sevoflurane emergence agitation for all procedures reported an incidence of 26% [18] . Our lower incidence of agitation is likely related to a lower overall dose of sevoflurane, given the relatively short duration of the test. The observation of sore throat has not been reported with sevoflurane anesthesia and may be related to preexisting illness, because there was no airway intervention or placement of nasoenteric tubes during the anesthesia. Although no radiologists reported that the studies were nondiagnostic, voiding was not achieved on the table in 4 patients. The radiologists' confidence in the examinations may be related to the observation of VUR in all of the children who did not void on the table. The proportion of children who did not void on the table was not significantly different from the control group in our study. The nonvoiding rate was similar to that reported by Stokland [4] for children who received midazolam (2 of 48 children did not void) and for children who received placebo (9 of 47 children did not void). Other studies concluded that oral midazolam does not alter the rate of micturition or postvoid residual urine volume, but these studies do not state the number of children who achieved on-table voiding [3, 5] . Bozkurt [19] showed that intranasal midazolam had no effect on urodynamic variables in children. Studies that report the use of nitrous oxide did not report the occurrence of voiding or reflux [8, 9] .
Sevoflurane did not have a significant effect on voiding in this study. The volume of residual urine after micturition is of concern, because 52% of patients had at least a moderate postvoid residual volume of urine. However, the proportion of unsedated children with moderate-to-large residual bladder volumes also was high, with no significant difference in the average residual bladder volume grading, therefore, it is difficult to attribute larger residual bladder volumes to sevoflurane. Residual urine could potentially limit the ability of a VCUG to detect low-grade reflux. It is unknown whether the absence of voiding or larger postvoid residual urine volumes had any effect on the observation of reflux; the 50% rate of reflux was higher than in the other studies, 31% and 16 % [4, 5] . The higher rate of reflux was in keeping with a high proportion of children who had previous VCUG, 50% of surveyed children, and 42% of all children who received sevoflurane. When children who received sevoflurane and with a history of VUR or previous VCUG were excluded, and the remaining group compared with age-and sex-matched unsedated controls, the incidence of reflux in both groups was lower, with the 36% incidence in the sevoflurane group comparable with other reported rates [4, 5] and not significantly different from the control group (42%). Therefore, it is unlikely that use of sevoflurane resulted in the observation of higher rates of VUR than in unsedated children.
The age of children who received sevoflurane for VCUG was older than the usual unsedated group at our institution, where the mean age was 29 months and the median age of 13 months. The older age of the patients who received sevoflurane likely reflects the referral pattern for sedation, with anesthesia being performed at the request of physicians and their patients, because most physicians would not expect infants to have a recollection of the procedure. The female predominance among the sedated group reflects the bias towards patients with VUR as urinary tract infection associated radiologic abnormalities are more common in females [20e22] .
The patients were not catheterized to quantitate the residual volumes of urine, which is a limitation of the grading system of residual volume. Recatheterization was not thought to be clinically acceptable because children were already awake at the time of voiding. Also, the volume of residual urine was estimated based on the last image of the bladder. Although this assumption could result in overestimation of the residual urine volumes, it is the standard practice at our institution for radiologists to obtain a final fluoroscopic image of the bladder after voiding.
Sevoflurane anesthetic did not add significant time to the duration of the VCUG, in keeping with its rapid induction and emergence times. A mean time of 18 minutes from start of anesthesia to recovery room was observed. In a busy pediatric radiology practice, there was concern that sedation could decrease productivity; however, the procedural time for a sedated VCUG is comparable with that for an unsedated VCUG; based on 15 consecutive unsedated patients in our practice, the median time was 15 minutes, with most examinations in the range of 14-16 minutes. There are no reports in the medical literature of the average procedural time of a VCUG. It was not possible to measure the examination time for the control group because initial starting times were not documented in the medical record.
The patients were referred for VCUG with anesthetic by a pediatric nephrologist, pediatric urologist, or pediatrician. The majority of children who had anesthesia had a previous medical procedure, including 50% of the children of survey respondents with a previous VCUG without sedation (42% of all patients who received sevoflurane). It would appear that a previous unpleasant experience with medical procedures affected the decision to request anesthesia and could have biased the proportion of caregivers who chose to respond to the survey and their responses. However, it is not standard clinical practice to sedate all children for VCUG; children with previous traumatic experience with medical procedures or those likely to be traumatized by VCUG are the group most likely to benefit from anesthesia. This group of patients was represented in the survey. Based on the survey, the majority of respondents had a positive response to the use of sevoflurane, with most indicating that the procedure seemed easier for the child with sevoflurane and easier than previous unsedated VCUG experiences. The majority of respondents also thought that the anesthetic experience lessened their child's anxiety about future medical procedures; there has been concern raised about VCUG without sedation resulting in fear of future medical procedures [1] .
One limitation of the survey was that it was sent only to the group that received sevoflurane anesthesia and the questions were directed towards the sedation VCUG experience generally rather than to sevoflurane in particular. Therefore, these generally positive responses, although obtained in the context of sevoflurane anesthesia for VCUG, were without comparison to another agent or placebo, and may have reflected a general preference for sedation. However, sevoflurane anesthesia for VCUG did not result in a significant proportion of negative responses. Also, only 35% of the survey respondents were in the room for the entire VCUG, so positive response may have been related to parents' absence from a portion of the VCUG. Of the survey respondents who witnessed the entire VCUG, 81% had a positive impression. The caregivers of patients who received no sedation were not surveyed, and their rate of satisfaction with the VCUG experience is unknown. All of the patients' caregivers did not participate in the survey, therefore, the survey numbers are relatively small, and the results are difficult to generalize.
A limitation of this study was its retrospective nature. Postanesthetic responses, such as agitation, were not quantified. There was no placebo, because it was not ethical to use a placebo when patients were expecting an anesthetic. A comparison agent, such as propofol, was not used because clinical experience by the anesthesiologists and radiologists involved quickly showed sevoflurane to be the preferable agent, based on very long emergence times with propofol. There was no comparison with conscious sedation, such as midazolam, nitrous oxide, or fentanyl, because, at our institution, radiologists are not permitted to administer this agent, and anesthesiologists do not use these agents for this purpose. Therefore, a comparison group could not ethically be used. It remains necessary to evaluate anesthetic agents, such as sevoflurane, commonly used by anesthesiologists for radiologic procedures.
An ideal anesthetic agent should have no adverse effects, should be acceptable to patients, have rapid induction and emergence times, and should have no smooth-muscle relaxation qualities so that voiding and the occurrence of VUR are not affected. Midazolam and nitrous oxide have demonstrated these properties. Sevoflurane, theoretically, is less ideal because it has smooth-muscle relaxation properties [13] , but there was no effect on voiding or the prevalence of VUR in this study. Sevoflurane satisfied the other criteria for an ideal anesthetic agent for VCUG in this study.
Conclusion
Sevoflurane was a satisfactory anesthetic agent for pediatric VCUG in this study, based on safety, acceptability to patients, and no obvious influence on the diagnostic quality of VCUG. It was safe, with no cardiorespiratory events and minimal adverse effects in our limited experience. Patients' caregivers demonstrated generally positive responses when surveyed about the anesthetic experience with sevoflurane, which suggests that the agent generally was acceptable to patients This anesthetic agent was acceptable to the radiologist, without significant effect on the diagnostic quality of the voiding cystourethrogram and without adding significantly to the time required to perform the examination.
